TY - JOUR
T1 - Rationale, design, and baseline characteristics of a community-based comparative effectiveness trial to prevent type 2 diabetes in economically disadvantaged adults
T2 - The RAPID Study
AU - Ackermann, Ronald T.
AU - Finch, Emily A.
AU - Schmidt, Karen K.
AU - Hoen, Helena M.
AU - Hays, Laura M.
AU - Marrero, David G.
AU - Saha, Chandan
N1 - Funding Information:
Support for this study was provided by the National Institute of Diabetes and Digestive and Kidney Diseases ( R18 DK079855 ) and the Robert Wood Johnson Foundation (# 57398 ). R.T. Ackermann is also supported by the Northwestern University Clinical and Translational Sciences Institute ( UL1RR025741 ). We recognize the DPP Study Group and specifically the Lifestyle Resource Core at the University of Pittsburgh, who led the development of the initial DPP intervention. We would also like to recognize the support and participation of the YMCA of Greater Indianapolis, the providers and staff of IU Medical Group-Primary Care, the Regenstrief Institute, Inc., and all RAPID Study participants.
PY - 2014/1
Y1 - 2014/1
N2 - Reaching Out and Preventing Increases in Diabetes (RAPID) is a community-based randomized trial evaluating the comparative costs and effectiveness of a group-based adaption of the DPP lifestyle intervention developed and implemented in partnership with the YMCA. RAPID enrolled adult primary care patients, with BMI 24kg/m2 or higher and abnormal glucose metabolism (HbA1c 5.7-6.9% or fasting plasma glucose 100-125mg/dL). 509 participants were enrolled and randomized to one of two groups: standard clinical advice plus free-of-charge access to a group-based adaption of the DPP offered by the Y, versus standard clinical advice alone. Key outcomes for future analysis will include differences in body weight and other cardiovascular risk factors over a 24-month intervention period.At baseline, RAPID participants had a mean (SD) age of 51±12.1years, weight of 225.1±56.2lbs, and BMI of 36.9±8.6kg/m2. 70.7% were women, 57.2% were African American, 35.4% were non-Hispanic White, and 3.2% were Hispanic. Mean HbA1c was 6.05±0.34%. Additionally, 55.4% of participants had a baseline systolic blood pressure of ≥130mmHg, 33.1% had a total blood cholesterol exceeding 200mg/dL, and 74% reported a household income of <$25,000. The RAPID Study successfully randomized a large cohort of participants with a wide distribution of age, body weight, and race who are at high risk for developing type 2 diabetes.
AB - Reaching Out and Preventing Increases in Diabetes (RAPID) is a community-based randomized trial evaluating the comparative costs and effectiveness of a group-based adaption of the DPP lifestyle intervention developed and implemented in partnership with the YMCA. RAPID enrolled adult primary care patients, with BMI 24kg/m2 or higher and abnormal glucose metabolism (HbA1c 5.7-6.9% or fasting plasma glucose 100-125mg/dL). 509 participants were enrolled and randomized to one of two groups: standard clinical advice plus free-of-charge access to a group-based adaption of the DPP offered by the Y, versus standard clinical advice alone. Key outcomes for future analysis will include differences in body weight and other cardiovascular risk factors over a 24-month intervention period.At baseline, RAPID participants had a mean (SD) age of 51±12.1years, weight of 225.1±56.2lbs, and BMI of 36.9±8.6kg/m2. 70.7% were women, 57.2% were African American, 35.4% were non-Hispanic White, and 3.2% were Hispanic. Mean HbA1c was 6.05±0.34%. Additionally, 55.4% of participants had a baseline systolic blood pressure of ≥130mmHg, 33.1% had a total blood cholesterol exceeding 200mg/dL, and 74% reported a household income of <$25,000. The RAPID Study successfully randomized a large cohort of participants with a wide distribution of age, body weight, and race who are at high risk for developing type 2 diabetes.
KW - Community research
KW - Lifestyle intervention
KW - Overweight/obesity
KW - Pre-diabetes
KW - Primary prevention
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=84888079162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888079162&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2013.10.003
DO - 10.1016/j.cct.2013.10.003
M3 - Article
C2 - 24177413
AN - SCOPUS:84888079162
SN - 1551-7144
VL - 37
SP - 1
EP - 9
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
IS - 1
ER -